{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:44:58Z","timestamp":1761129898370,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.urolonc.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:38:22Z","timestamp":1625801902000},"page":"736.e9-736.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up"],"prefix":"10.1016","volume":"39","author":[{"given":"Dominik A.","family":"Barth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazanin","family":"Sareban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea K.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa A.J.","family":"Daller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Maria","family":"Matzhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hutterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Smolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Mischinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob M.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Seles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Mannweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bauernhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Pummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Zigeuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schlenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2021.06.005_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.urolonc.2021.06.005_bib0002","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11255-012-0165-5","article-title":"Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survival","volume":"44","author":"Pichler","year":"2012","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"10.1016\/j.urolonc.2021.06.005_bib0003","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00345-018-2309-4","article-title":"Prognostic factors and prognostic models for renal cell carcinoma: a literature review","volume":"36","author":"Klatte","year":"2018","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eururo.2008.11.033","article-title":"External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology","volume":"57","author":"Zigeuner","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2011.07.034","article-title":"External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology","volume":"186","author":"Pichler","year":"2011","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2021.06.005_bib0006","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.urolonc.2014.04.001","article-title":"Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma","volume":"32","author":"Hutterer","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.juro.2015.01.083","article-title":"The Preoperative AST\/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma","volume":"194","author":"Bezan","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/bjc.2016.393","article-title":"Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma","volume":"116","author":"Dalpiaz","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0009","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3389\/fcell.2020.00828","article-title":"Circulating non-coding rnas in renal cell carcinoma\u2014pathogenesis and potential implications as clinical biomarkers","volume":"8","author":"Barth","year":"2020","journal-title":"Front Cell Devel Biol"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-10-55","article-title":"Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma","volume":"10","author":"Redova","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canep.2016.06.005","article-title":"ABO blood group and risk of cancer: A register-based cohort study of 1.6 million blood donors","volume":"44","author":"Vasan","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.06.005_bib0012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.hoc.2015.01.003","article-title":"Hemolysis from ABO Incompatibility","volume":"29","author":"Simmons","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.urolonc.2021.06.005_bib0013","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/wsbm.1355","article-title":"Blood type biochemistry and human disease","volume":"8","author":"Ewald","year":"2016","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0014","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0015","doi-asserted-by":"crossref","unstructured":"Teppan J, Barth DA, Prinz F, Jonas K, Pichler M, Klec C. Involvement of long non-coding rnas (lncRNAs) in tumor angiogenesis. noncoding RNA 2020;6(4):42. doi:10.3390\/ncrna6040042.","DOI":"10.3390\/ncrna6040042"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/s12893-015-0094-1","article-title":"Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jss.2015.10.039","article-title":"Prognostic value of ABO blood group in patients with gastric cancer","volume":"201","author":"Xu","year":"2016","journal-title":"J Surg Res"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-319","article-title":"AB0 blood group and prognosis in patients with pancreatic cancer","volume":"12","author":"Rahbari","year":"2012","journal-title":"BMC Cancer"},{"issue":"11 Pt B","key":"10.1016\/j.urolonc.2021.06.005_bib0019","first-page":"E641","article-title":"ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma","volume":"110","author":"Kaffenberger","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2021.06.005_bib0020","first-page":"2765","article-title":"Prognostic significance of blood type A in patients with renal cell carcinoma","volume":"13","author":"Ko","year":"2016","journal-title":"Urol J"},{"issue":"8","key":"10.1016\/j.urolonc.2021.06.005_bib0021","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00432-015-1908-3","article-title":"Prognostic value of ABO blood group in patients with renal cell carcinoma: single-institution results from a large cohort","volume":"141","author":"Lee","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5b","key":"10.1016\/j.urolonc.2021.06.005_bib0022","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1111\/bju.12436","article-title":"Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC)","volume":"113","author":"de Martino","year":"2014","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2021.06.005_bib0023","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/trf.15907","article-title":"A 24-base pair deletion in the ABO gene causes a hereditary splice site defect: a novel mechanism underlying ABO blood group O","volume":"60","author":"Matzhold","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.urolonc.2021.06.005_bib0024","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.juro.2017.07.036","article-title":"Blood platelet volume represents a novel prognostic factor in patients with nonmetastatic renal cell carcinoma and improves the predictive ability of established prognostic scores","volume":"198","author":"Seles","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0026","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0304-4165(99)00183-X","article-title":"Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer","volume":"1473","author":"Hakomori","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.urolonc.2021.06.005_bib0027","first-page":"434","article-title":"The prognostic value of ABO blood group in cancer patients","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"4","key":"10.1016\/j.urolonc.2021.06.005_bib0028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10408363.2012.708647","article-title":"ABO blood group, hypercoagulability, and cardiovascular and cancer risk","volume":"49","author":"Franchini","year":"2012","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2021.06.005_bib0029","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.tp.0000231697.15817.51","article-title":"Blood group A and B antigen expression in human kidneys correlated to A1\/A2\/B, Lewis, and secretor status","volume":"82","author":"Breimer","year":"2006","journal-title":"Transplantation"},{"issue":"1-6","key":"10.1016\/j.urolonc.2021.06.005_bib0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0031","first-page":"29","article-title":"Relation of ABO and RH blood groups with renal cell carcinoma","volume":"53","author":"Giannopoulos","year":"1985","journal-title":"Acta Urol Belg"},{"issue":"6","key":"10.1016\/j.urolonc.2021.06.005_bib0032","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0090-4295(76)90529-X","article-title":"ABO blood group in relation to hypernephroma","volume":"8","author":"Desai","year":"1976","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2021.06.005_bib0033","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1537-2995.2004.03338.x","article-title":"Retrovirus Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial\/ethnic groups in the United States","volume":"44","author":"Garratty","year":"2004","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.urolonc.2021.06.005_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4773-z","article-title":"Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2021.06.005_bib0035","doi-asserted-by":"crossref","unstructured":"Pichler R, Comp\u00e9rat E, Klatte T, Pichler M, Loidl W, Lusuardi L, et al. Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope? cancers (Basel) 2019;11(3):422. doi:10.3390\/cancers11030422.","DOI":"10.3390\/cancers11030422"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:38Z","timestamp":1761042218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921002647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1078143921002647"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}